title: Studying cancer treatment in the elderly patient population.
abstract: BACKGROUND
  Data relating to cancer treatment in the older patient population are limited because older individuals have been under-represented in clinical trials. The goal of this review was to establish which factors hinder the participation of older individuals to clinical trials and to examine possible solutions.
  
  
  METHODS
  The literature relating to cancer treatment in the older patient population was reviewed.
  
  
  RESULTS
  The benefit of systemic cancer treatment may decrease with age, and risks may be increased due to reduced life expectancy and reduced tolerance of stress in the older population. Therefore, a multipronged approach is recommended for clinical studies in these patients, including phase 2 studies limited to persons 70 years of age and older, stratification by life expectancy and predicted treatment tolerance in phase 3 studies, and registration studies to establish predictive variables for treatment-related toxicity in older individuals.
  
  
  CONCLUSIONS
  A combination of prospective and registration studies may supply adequate information to study cancer treatments in the older patient population.
authors: Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA. Lodovico.Balducci@Moffitt.org.
authors: Lodovico
authors: L
authors: Balducci
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods